SynthesisThe Cochrane database of systematic reviews2003
Antidepressants for smoking cessation.
Synthesis in The Cochrane database of systematic reviews, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2014Pooled it
- Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Pooled it
- Impact of a board-game approach on current smokers: a randomized controlled trial.Substance abuse treatment, prevention, and policy · 2013Trial
- Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2007Trial
- An uncontrolled trial of cytisine (Tabex) for smoking cessation.Tobacco control · 2006Trial
- Practice-based referrals to a tobacco cessation quit line: assessing the impact of comparative feedback vs general reminders.Annals of family medicineTrial
- Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence.The pharmacogenomics journalTrial
- Evaluating smoking cessation strategies in thoracic surgery outpatient clinics.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2024Article
- Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Review
- A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback.Genes, brain, and behavior · 2013Article
- Why do cancer patients smoke and what can providers do about it?Community oncology · 2012Article
- Depression, diabetes, and chronic disease risk factors among US women of reproductive age.Preventing chronic disease · 2011Article
- Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists.Current oncology reports · 2007Review
- Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area.Biochemical pharmacology · 2007Article
- Association between depressive mood and cigarette smoking in a large Italian sample of smokers intending to quit: implications for treatment.Internal and emergency medicine · 2007Article
- [Pharmacological relapse prevention in alcohol and tobacco dependence].Der Internist · 2007Review
- Non-atherosclerotic vascular disease in the young.Journal of thrombosis and thrombolysis · 2005Article
- Bupropion effects on aggressiveness and anxiety in OF1 male mice.Psychopharmacology · 2005Article
- Bupropion and other non-nicotine pharmacotherapies.BMJ (Clinical research ed.) · 2004Review
Corrections and comments
- Updated by
- Update of
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere at least two reasons to believe antidepressants might help in smoking cessation. Depression may be a symptom of nicotine withdrawal, and smoking cessation sometimes precipitates depression. In some individuals, nicotine may have antidepressant effects that maintain smoking. Antidepressants may substitute for this effect.
objectivesThe aim of this review is to assess the effect of antidepressant medications in aiding long-term smoking cessation. The drugs include bupropion; doxepin; fluoxetine; imipramine; moclobemide; nortriptyline; paroxetine; selegiline; sertraline, tryptophan and venlafaxine. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register which includes trials indexed in MEDLINE, EMBASE, SciSearch and PsycINFO, and other reviews and meeting abstracts, in December 2002. SELECTION CRITERIA: We considered randomized trials comparing antidepressant drugs to placebo or an alternative therapeutic control for smoking cessation. For the meta-analysis, we excluded trials with less than six months follow-up. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of study population, the nature of the drug therapy, the outcome measures, method of randomization, and completeness of follow-up. The main outcome measure was abstinence from smoking after at least six months follow-up in patients smoking at baseline, expressed as an odds ratio (OR). We used the most rigorous definition of abstinence for each trial, and biochemically validated rates if available. Where appropriate, we performed meta-analysis using a fixed effects model. MAIN
resultsThere was one trial each of moclobemide, sertraline and venlafaxine, two of fluoxetine, five of nortriptyline, and twenty trials of bupropion. In the bupropion trials, 18 had a placebo arm, two of which tested long-term use to prevent relapse. Nine of the bupropion trials have been published in full. Nortriptyline (five trials, OR 2.80, 95% CI 1.81 - 4.32) and bupropion (16 trials, OR 1.97, 95% CI 1.67 - 2.34) both increased the odds of cessation. In one trial the combination of bupropion and nicotine patch produced slightly higher quit rates than patch alone, but this was not replicated in a second study. Two trials of extended therapy with bupropion to prevent relapse after initial cessation have failed to detect a long-term benefit. REVIEWER'S
conclusionsThe antidepressants bupropion and nortriptyline can aid smoking cessation but selective serotonin reuptake inhibitors (e.g. fluoxetine) do not.
Indexed as
Identifiers
12804385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.